Spotlight on tesamorelin in HIV-associated lipodystrophy

Tesamorelin effectively reduced visceral adipose tissue in two 26-week trials without affecting subcutaneous fat, the only approved treatment for HIV lipodystrophy.

Abstract

Tesamorelin (Egrifta™) is a synthetic analog of human growth hormone-releasing hormone (also known as growth hormone-releasing factor) that stimulates the synthesis and release of endogenous growth hormone.. It is the first and, so far, only treatment indicated for the reduction of excess abdominal fat in patients with HIV-associated lipodystrophy.. This article reviews the pharmacological.

Key Findings

It is the first and, so far, only treatment indicated for the reduction of excess abdominal fat in patients with HIV-associated lipodystrophy. | Subcutaneous tesamorelin was effective in reducing visceral adipose tissue (VAT), but did not affect subcutaneous adipose tissue to a clinically significant extent in two 26-week, well designed, clini...

Study Design

Review article